Novateur Ventures explores new strategy to reduce hyperinflammatory response caused by COVID-19

Novateur’s research proposes simple treatment paradigm using two generic drugs, directed to blocking inflammation in airways of patients with asthma, to target hyper-inflammatory response insevere COVID-19. This will be accomplished by combination of leukotriene biosynthesis blocker zileuton (Zyflo® controlled release formulation) and inhibitor of cysteinyl leukotriene 1 receptor montelukast (Singulair®). Both these agents have been on market for many years, and their activity and side effects in humans are well known.